William Owens, MD
Family Medicine · Baton Rouge, LANPI 1356795371
Payments from drug & device makers
Across 179 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$784
- GSK$198
- Lilly USA, LLC$148
- Bayer$141
- Novo Nordisk$128
- plus $612 from 19 others
What the payments were for
- Food & beverage$3,253100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 86 | $1,241 |
| AstraZeneca | 23 | $784 |
| GSK | 12 | $198 |
| Lilly USA, LLC | 8 | $148 |
| Bayer | 10 | $141 |
| Novo Nordisk | 8 | $128 |
| Pfizer | 5 | $97 |
| Boston Scientific | 1 | $97 |
| Amarin Pharma, Inc. | 4 | $62 |
| Amgen(2 entities) | 3 | $52 |
| Nevro Corp. | 2 | $47 |
| Boehringer Ingelheim | 2 | $31 |
| Merck | 2 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Novartis | 1 | $21 |
| Eisai Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Exact Sciences | 1 | $18 |
| Antares Pharma, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
| Nabriva Therapeutics, PLC | 1 | $12 |
| Hikma Pharmaceuticals USA | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 2 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$355
How this compares
$3,253 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 29 | $30,000 |
| FarxigaDapagliflozin Propanediol | 22 | $17,738 |
| MounjaroTirzepatide | 13 | $13,806 |
| SynjardyEmpagliflozin/Metformin Hcl | 16 | $9,803 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,053 |
| TradjentaLinagliptin | 12 | $5,927 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 66 | $1,735 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $1,368 |
| Duloxetine Hcl | 40 | $961 |
| Rosuvastatin Calcium | 82 | $952 |
| Pantoprazole Sodium | 64 | $784 |
| Atorvastatin Calcium | 120 | $718 |
| Amlodipine Besylate | 100 | $705 |
| Tamsulosin Hcl | 40 | $692 |
| Metoprolol Succinate | 53 | $674 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $128 | $30,00029 claims |
| AstraZenecaFarxiga | $784 | $17,73822 claims |
| Boehringer IngelheimSynjardy, Tradjenta | $31 | $15,73028 claims |
| Lilly USA, LLCMounjaro | $148 | $13,80613 claims |
| GSKTrelegy Ellipta | $198 | $9,05315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Baton Rouge
- Christine SmithBaton Rouge$185K
- Kevin DibenedettoBaton Rouge$80K
- Stan MaysBaton Rouge$15K
- Myles JaynesBaton Rouge$15K
- Yushen LeeBaton Rouge$14K
- Gerald BarberBaton Rouge$14K
- Vincent NguyenBaton Rouge$13K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.